The prognostic impact of karyotypic subgroups in myelodysplastic syndromes is strongly modified by sex
Open Access
- 1 May 2001
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 113 (2) , 347-356
- https://doi.org/10.1046/j.1365-2141.2001.02750.x
Abstract
The prognostic impact of karyotypic patterns in a consecutive series of 389 adult myelodysplastic syndromes (MDS) was investigated. Time period did not significantly influence the survival times. In the analyses, the MDS cases were subdivided into the cytogenetic subgroups used in the International Prognostic Scoring System, i.e. favourable [–Y, del(5q) or del(20q) as single aberrations or normal karyotype, n = 241], poor [−7, del(7q), der(1;7) or complex karyotypes, i.e. ≥ three abnormalities, n = 89] and intermediate (other aberrations, n = 59). The survival times correlated well with the prognostic subgroups, confirming that the cytogenetic classification was valid. Expressed as hazard ratios (HRs), with the favourable subgroup as the reference, the intermediate and poor subgroup HRs increased to 1·5 (95% confidence interval, 1·1–2·1) and 3·2 (2·4–4·1) respectively. Sex, age, morphological subtype and smoking habits significantly modified this prognostic impact. Shorter survival was detected for men in the favourable and the intermediate subgroups, but not in the poor prognosis subgroup. Using women in the favourable subgroup as the reference and adjusting for age, the HR for men was 1·6 (1·2–2·1) in the favourable subgroup. Adjusting for smoking habits as well decreased the HR to 1·4 (1·1–2·0) and, when also excluding cases with del(5q) as the sole anomaly, no significant difference could be discerned [HR 1·2 (0·9–1·6], suggesting that the better outcome for women in the favourable subgroup was mainly as a result of the ‘5q‐syndrome’ and to smoking habits. In the intermediate subgroup, the corresponding HRs were 3·0 (1·5–6·0) when adjusted for age and 2·7 (1·3–5·5) when also adjusted for smoking habits. Different survival times between men and women have never previously been reported for this MDS group. Although it remains to be elucidated whether environmental and/or constitutional factors cause the observed sex‐related difference, these observations have obvious clinical ramifications, not least in designing and evaluating therapy protocols.Keywords
This publication has 34 references indexed in Scilit:
- Refractory anemia with excess of blasts: A multivariate analysis of prognostic factors in 91 patients and a simplified scoring system for predicting survivalEuropean Journal of Haematology, 2009
- High resolution analysis of the 5q-marker chromosome in refractory anemiaHereditas, 2008
- Prognostic factors in myelodysplastic syndromes: critical analysis of the impact of age and gender and failure to identify a very‐low‐risk group using standard mortality ratio techniquesBritish Journal of Haematology, 1996
- NRAS mutations are rare in acute myeloid leukaemias with t(8;21) or inv(16)European Journal of Haematology, 1996
- The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia: Proposals by the French ‐ American ‐ British Cooperative Leukaemia GroupBritish Journal of Haematology, 1994
- Trisomy 19 as the sole chromosomal anomaly in hematologic neoplasmsCancer Genetics and Cytogenetics, 1994
- Chronic myelomonocytic leukemia: Single entity or heterogeneous disorder?: A prospective multicenter study of 100 patientsCancer Genetics and Cytogenetics, 1991
- Cigarette smoking, blast crisis, and survival in chronic myeloid leukemiaAmerican Journal of Hematology, 1990
- Bone marrow karyotype and prognosis in primary myelodysplastic syndromesEuropean Journal of Haematology, 1988
- Proposals for the classification of the myelodysplastic syndromesBritish Journal of Haematology, 1982